viveve

Advancing the Science of Women's Intimate Health

MAY 2019

Safe Harbor Statement

All statements in this presentation that are not based on historical fact are "forward looking statements". While management has based any forward-looking statements included in this presentation on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements.

Such risks, uncertainties, and other factors include, but are not limited to: (i) we currently do not have the ability to market our system in the U.S. for sexual function, vaginal laxity or stress urinary incontinence; (ii) we will need to obtain FDA clearance or approval for other indications, which may not be granted; (iii) our business is not profitable, and we may not be able to achieve profitability; (iv) we depend on distributors to market and sell our products and they may not be successful; (v) we currently have limited sales and marketing resources; (vi) the fluctuation of global economic conditions; (vii) the performance of management and our employees; (viii) our ability to obtain financing; (ix) competition and general economic conditions; and (x) other factors that are to be detailed in our periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements.

In the United States the Viveve System is indicated for use in general surgical procedures for electrocoagulation and hemostasis.
viveve

A women's intimate health company commercializing an innovative, clinically-proven, **proprietary platform technology (CMRF)** to address multiple unmet medical needs

In the United States the Viveve System is indicated for use in general surgical procedures for electrocoagulation and hemostasis.

Track Record of Commercial and Clinical Success

Demonstrated Commercial Growth

- Global installed base expansion – 746 Viveve Systems worldwide
- Over 35,000 treatment tips sold globally since inception
- Direct sales & distributor network - commercial footprint in over 60 countries

Significant Label Expansion Opportunity

- Five positive clinical studies in Vaginal Laxity/Sexual Function and Stress Urinary Incontinence (SUI)
- U.S. Sexual Function study enrollment completed – VIVEVE II
- International SUI study enrollment completed – LIBERATE-INT
- U.S. SUI study planned pending resubmission of IDE to FDA – LIBERATE-US

In the United States the Viveve System is indicated for use in general surgical procedures for electrocoagulation and hemostasis.
viveve

Designed for Women's Intimate Health Indications

Evolved to functional treatments through robust scientific and clinical research in women's intimate health conditions

2019

Significant reduction in manufacturing costs for entire platform

In the United States the Viveve System is indicated for use in general surgical procedures for electrocoagulation and hemostasis.
viveve

Proven Solution for Women's Intimate Health Indications



Model represents nominal tissue parameters

Viveve® CMRF

- monopolar radiofrequency with controlled cooling -

- Allows depth of tissue penetration while maintaining patient comfort and safety
- Single treatment
- Consistent patient outcomes
- Durable results

In the United States the Viveve System is indicated for use in general surgical procedures for electrocoagulation and hemostasis.
viveve

Large Unmet Need in Women's Intimate Health Indications

SEXUAL FUNCTION
U.S. TOTAL AVAILABLE MARKET

Adult Female Population[1]: ~128M

Laxity Prevalent Population[2]:
22% = ~27M

Adj. Prevalent Population[3]:
4% = ~5M
(Treatable premenopausal with ability to pay)

CASH PAY
US TAM ~ $2B
WW TAM ~ $4B

Strong overlap in prevalent population

Opportunity to bundle

STRESS URINARY INCONTINENCE
U.S. TOTAL AVAILABLE MARKET

Adult Female Population[1]: ~128M

SUI Prevalent Population[4]:
28% = ~36M

Adj. Prevalent Population[5]:
9% = ~11M
(Treatable premenopausal with access to care)

CASH PAY
US TAM ~ $6B
WW TAM ~ $12B

REIMBURSEMENT
US TAM ~ $14B
WW TAM ~ $20B

In the United States the Viveve System is indicated for use in general surgical procedures for electrocoagulation and hemostasis.
viveve

viveve

Advancing the Science of Women's Intimate Health

VIVEVE II STUDY

April 2020
12-month final data readout
Sexual Function

Liberate INTERNATIONAL

July 2019
6-month final data readout
Stress Urinary Incontinence

Liberate UNITED STATES

End 2020 / Early 2021
12-month data final readout
Stress Urinary Incontinence

In the United States the Viveve System is indicated for use in general surgical procedures for electrocoagulation and hemostasis.

VIVEVE II STUDY

- Completed patient enrollment March 2019 – 250 patients at 19 active clinical sites at 1:1 randomization
- Primary efficacy endpoint: mean change from baseline in total Female Sexual Function Index (FSFI) score at 12 months
- Study to support FDA clearance - may lead to the first ever overall sexual function claim for women in the U.S.
- Expecting end Q1 2020 readout of final 12-month data*



* Timelines based on current company estimates.

In the United States the Viveve System is indicated for use in general surgical procedures for electrocoagulation and hemostasis.
viveve

Liberate INTERNATIONAL

- Completed patient enrollment in January 2019 – 99 patients at 9 active clinical sites at 2:1 randomization
- Primary efficacy endpoint: MCFB 1hr Pad Weight Test at 6-months
- SAP: **50% MCFB** in treated group vs **30% MCFB** in control group (sham) – **20% Difference**
- Expecting early Q3 2019 readout of final 6-month data*
- Study to support international SUI clearances in 35+ countries



* Timelines based on current company estimates.

In the United States the Viveve System is indicated for use in general surgical procedures for electrocoagulation and hemostasis.
viveve

Liberate
UNITED STATES

- IDE submitted in mid-September – 2 rounds questions - protocol, SAP and other issues resolved
- Conducting short acute animal tissue study to demonstrate safety of SUI protocol – 1H 2019
- Total 240 patients; 2:1 randomization
- SAP: **50% of patients** > 50% reduction 1hr Pad Weight Test treated group vs **27% of patients** > 50% reduction 1hr Pad Weight Test in control (sham) at 12-months – **23% Difference**
- Expecting end of 2020 / early 2021 readout of final 12-month data*



* Timelines based on current company estimates.

In the United States the Viveve System is indicated for use in general surgical procedures for electrocoagulation and hemostasis.
viveve

Significant Clinical & Regulatory Milestones Forthcoming



Five of eight major clin/reg milestones towards label expansion are occurring in the next 12 months

In the United States the Viveve System is indicated for use in general surgical procedures for electrocoagulation and hemostasis.

viveve

Leading Women's Intimate Health

- Track record of commercial success
- IP protected platform technology designed specifically for Women's Intimate Health Indications
- Most robust clinical evidence in industry focused on vaginal laxity/sexual function & SUI
- Multi-billion market opportunities forthcoming through near-term clinical readouts and regulatory clearances

In the United States the Viveve System is indicated for use in general surgical procedures for electrocoagulation and hemostasis.

Advancing the Science of Women's Intimate Health

NASDAQ: VIVE

In the United States the Viveve System is indicated for use in general surgical procedures for electrocoagulation and hemostasis.